Frazis on AI and Aussie biotech
Frazis on AI and Aussie biotech
About this video
Michael Frazis from Frazis Capital Partners highlights the impact of Chinese startup, DeepSeek, which has launched a cost-efficient AI model. This move sparks debate about the sustainability of business models like OpenAI's, especially as DeepSeek's AI overtakes US rival ChatGPT in downloads.
He observes how foundational models are evolving, with questions on capital expenditures affecting valuations. Michael notes companies like Apple and AWS may benefit, while OpenAI faces challenges. He examines market responses, where semiconductors highlight cyclical risks in tech investments.
In Australian biotech, Michael sees potential in companies like Clarity Pharmaceuticals (ASX:CU6) and the promising landscape despite recent sell-offs. He maintains a strong focus on Australian healthcare, remaining optimistic about companies awaiting US approvals and further growth.